news
EMA recommends RoActemra in adults with severe COVID-19
The European Medicines Agency (EMA)’s human medicines committee (CHMP) recommends extending RoActemra's indication to include COVID-19 patients receiving systemic treatment.
List view / Grid view
RoActemra (tocilizumab)
article
COVID-19 antibody therapeutics – where are they now?
In this article, EPR’s Hannah Balfour explores the current usage of monoclonal antibody therapies for COVID-19, with commentary from Professor Adrian Streinu-Cercel of the Carol Davila University of Medicine and Pharmacy.
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
Roche and Chugai’s new subcutaneous formulation of RoActemra® (tocilizumab) gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
news
Roche’s RoACTEMRA shows long-term efficacy in monotherapy and also benefits in early rheumatoid arthritis
13 June 2013 | By Roche
Roche announced data from two phase III studies...
news
Roche’s RoACTEMRA approved in EU to treat children with rare form of arthritis
10 June 2013 | By Roche
“This approval comes earlier than expected, just one month following the positive CHMP opinion...”
